Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Company Performance - Bristol Myers Squibb (BMY) closed at $44.16, reflecting a -1.67% change from the previous day, underperforming the S&P 500's daily loss of 0.29% [1] - Over the last month, BMY shares decreased by 4.87%, contrasting with the Medical sector's loss of 0.33% and the S&P 500's gain of 3.08% [1] Upcoming Earnings Report - The company is set to release its earnings on October 30, 2025, with projected earnings of $1.65 per share, indicating a year-over-year decline of 8.33% [2] - The Zacks Consensus Estimate for revenue is $11.77 billion, down 1.03% from the previous year [2] Full Year Estimates - Analysts expect full-year earnings of $6.5 per share and revenue of $47.31 billion, representing changes of +465.22% and -2.06% respectively from last year [3] Analyst Estimates and Market Sentiment - Recent adjustments to analyst estimates for Bristol Myers Squibb reflect evolving short-term business trends, with positive revisions indicating analyst optimism [4] - The Zacks Rank system, which incorporates estimate changes, currently rates Bristol Myers Squibb as 3 (Hold) [6] Valuation Metrics - Bristol Myers Squibb has a Forward P/E ratio of 6.91, significantly lower than the industry average of 19.48 [7] - The company has a PEG ratio of 2.3, compared to the industry average PEG ratio of 1.68 [7] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, holds a Zacks Industry Rank of 98, placing it in the top 40% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]